| Dimple Jaswal, APRN | |
|
1 Medical Center Dr, Lebanon, NH 03756-0001 | |
| (603) 650-5000 | |
| Not Available |
| Full Name | Dimple Jaswal |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Adult Health |
| Location | 1 Medical Center Dr, Lebanon, New Hampshire |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073261905 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 163W00000X | Registered Nurse | 084495-21 (New Hampshire) | Secondary |
| 363LA2200X | Nurse Practitioner - Adult Health | 084495-23 (New Hampshire) | Primary |
| Entity Name | Mary Hitchcock Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023092053 PECOS PAC ID: 4486561164 Enrollment ID: O20031126000258 |
News Archive
A nationwide, government-sponsored study finds that people with a common form of diabetic retinopathy can benefit from a medication first developed to combat another potentially blinding disease, age-related macular degeneration (AMD). Treating diabetic macular edema (DME) with ranibizumab (Lucentis) eye injections, plus laser treatment if needed, appears to result in better vision than laser treatment alone, according to the Diabetic Retinopathy Clinical Research (DRCR) Network study published today in Ophthalmology online, the journal of the American Academy of Ophthalmology (Academy). DME is the main cause of vision loss in people with diabetes mellitus.
Identifying more effective treatment strategies tailored to individual responses for patients overcoming addiction to cocaine is the focus of a new clinical trial at McGovern Medical School at The University of Texas Health Science Center at Houston.
Waiting too long after a hysterectomy to begin radiation therapy may increase the risk of uterine cancer recurrence, according to a new study from researchers at Henry Ford Hospital in Detroit.
Halozyme Therapeutics, Inc. today announced a global collaboration and license agreement with Eli Lilly and Company to develop and commercialize products combining proprietary Lilly compounds with Halozyme's ENHANZE platform.
Eden Biodesign, a globally-integrated provider of biopharmaceutical process development, cGMP manufacturing and consultancy services, today announced it has been selected by Biotecnol SA to manufacture Cardiotrophin-1 for potential use in certain liver indications.
› Verified 8 days ago
| Entity Name | Dartmouth-hitchcock Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548210198 PECOS PAC ID: 4183537509 Enrollment ID: O20040809000442 |
News Archive
A nationwide, government-sponsored study finds that people with a common form of diabetic retinopathy can benefit from a medication first developed to combat another potentially blinding disease, age-related macular degeneration (AMD). Treating diabetic macular edema (DME) with ranibizumab (Lucentis) eye injections, plus laser treatment if needed, appears to result in better vision than laser treatment alone, according to the Diabetic Retinopathy Clinical Research (DRCR) Network study published today in Ophthalmology online, the journal of the American Academy of Ophthalmology (Academy). DME is the main cause of vision loss in people with diabetes mellitus.
Identifying more effective treatment strategies tailored to individual responses for patients overcoming addiction to cocaine is the focus of a new clinical trial at McGovern Medical School at The University of Texas Health Science Center at Houston.
Waiting too long after a hysterectomy to begin radiation therapy may increase the risk of uterine cancer recurrence, according to a new study from researchers at Henry Ford Hospital in Detroit.
Halozyme Therapeutics, Inc. today announced a global collaboration and license agreement with Eli Lilly and Company to develop and commercialize products combining proprietary Lilly compounds with Halozyme's ENHANZE platform.
Eden Biodesign, a globally-integrated provider of biopharmaceutical process development, cGMP manufacturing and consultancy services, today announced it has been selected by Biotecnol SA to manufacture Cardiotrophin-1 for potential use in certain liver indications.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dimple Jaswal, APRN 6 Buttonbush Ln, Litchfield, NH 03052-8001 Ph: (407) 738-3410 | Dimple Jaswal, APRN 1 Medical Center Dr, Lebanon, NH 03756-0001 Ph: (603) 650-5000 |
News Archive
A nationwide, government-sponsored study finds that people with a common form of diabetic retinopathy can benefit from a medication first developed to combat another potentially blinding disease, age-related macular degeneration (AMD). Treating diabetic macular edema (DME) with ranibizumab (Lucentis) eye injections, plus laser treatment if needed, appears to result in better vision than laser treatment alone, according to the Diabetic Retinopathy Clinical Research (DRCR) Network study published today in Ophthalmology online, the journal of the American Academy of Ophthalmology (Academy). DME is the main cause of vision loss in people with diabetes mellitus.
Identifying more effective treatment strategies tailored to individual responses for patients overcoming addiction to cocaine is the focus of a new clinical trial at McGovern Medical School at The University of Texas Health Science Center at Houston.
Waiting too long after a hysterectomy to begin radiation therapy may increase the risk of uterine cancer recurrence, according to a new study from researchers at Henry Ford Hospital in Detroit.
Halozyme Therapeutics, Inc. today announced a global collaboration and license agreement with Eli Lilly and Company to develop and commercialize products combining proprietary Lilly compounds with Halozyme's ENHANZE platform.
Eden Biodesign, a globally-integrated provider of biopharmaceutical process development, cGMP manufacturing and consultancy services, today announced it has been selected by Biotecnol SA to manufacture Cardiotrophin-1 for potential use in certain liver indications.
› Verified 8 days ago
Mrs. Janice M Brennan, APRN Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1 Medical Center Dr, Dhmc Department Of Occupation Medicine, Lebanon, NH 03756 Phone: 603-560-5000 Fax: 603-650-0787 | |
Meredith Anne Stringer, NP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1 Medical Center Dr, Lebanon, NH 03756 Phone: 603-650-5000 | |
Carol Williams-suich, ARNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 5 Alice Peck Day Dr, Lebanon, NH 03766 Phone: 603-448-3122 Fax: 603-448-7491 | |
Cassandra M Godzik, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: One Medical Center Dr, Lebanon, NH 03756 Phone: 603-650-7232 | |
Deann Opal Mcnamara, APRN Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1 Medical Center Dr, Lebanon, NH 03756 Phone: 603-650-5922 | |
Emily L Swann, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Dr, Lebanon, NH 03756 Phone: 603-650-6224 | |
Molly P Keady, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Center Dr, Lebanon, NH 03756 Phone: 603-650-8622 |